variantt Email Formats

About variantt

Most drug discovery programs fail in Phase II, often because the wrong target was chosen at the very start. Each failed Phase II can cost $50M or more — and years of effort. Genetics evidence is the strongest predictor of clinical success. Programs backed by genetics are up to 3x more likely to succeed, yet most organisations lack the dedicated genetics expertise to harness these insights. Variantt is changing that. We’re building a platform that makes genetics evidence usable, clear, and actionable for drug discovery scientists. By integrating multiple trusted data sources and providing full provenance, Variantt helps R&D teams: Prioritise the right targets earlier. Validate hypotheses with causal genetics evidence. De-risk programs and avoid costly late-stage failures. Our goal is to make high-quality genetics insights available to any organisation — without the need for a full genetics department. 📩 Connect with us to learn more about early access, collaboration opportunities, or investment.

View contact profiles from variantt